Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satavaptan for prevention of recurrent ascites in cirrhosis (double-blind placebo-controlled study without diuretics)
2006-000135-10Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cirrhosis comparing Satavaptan arm with Placebo arm (2 arms). Primary endpoints: Number of ascites recurrences requiring therapeutic paracentesis within 12 weeks and Time to ascites recurrence requiring therapeutic paracentesis within 12 weeks. Started Mar 2006; status: completed.
02
Drugs
satavaptan
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2006-000135-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000135-10.